Research programme: proto oncogene protein c-myc inhibitors - Peptomyc
Alternative Names: OMO-101; Omomyc-based cell penetrating peptides - Peptomyc; Omomyc-CPPLatest Information Update: 28 Dec 2024
At a glance
- Originator Peptomyc; Vall d-Hebron Research Institute
- Class Antineoplastics; Peptides
- Mechanism of Action Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Cancer in Spain (Intranasal)
- 26 Oct 2022 Omomyc is still in preclinical development for Cancer in Spain
- 26 Oct 2022 Pharmacodynamics data from a preclinical study in Cancer presented at EORTC-NCI-AACR symposium (ENA 2022)